Shandong Xinhua Pharmaceutical Company Limited (HKG:0719)

HKG:0719 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	8,246	8,324	7,956	7,295	6,360	5,949
Other Revenue	126.63	142.44	144.78	207.82	200.54	56.85
Revenue	8,373	8,466	8,101	7,503	6,560	6,006
Revenue Growth (YoY)	2.59%	4.51%	7.97%	14.37%	9.23%	7.13%
Cost of Revenue	6,645	6,481	5,779	5,515	4,824	4,244
Gross Profit	1,728	1,985	2,321	1,988	1,736	1,762
Selling, General & Admin	819.66	1,017	1,287	1,106	929.12	943.96
Research & Development	372.5	413.18	419.24	345.66	341.37	298.35
Other Operating Expenses	61.46	35.88	92.18	65.31	59.27	60.28
Operating Expenses	1,263	1,475	1,809	1,522	1,332	1,303
Operating Income	465.07	510.63	512.15	465.87	403.67	458.77
Interest Expense	-43.32	-39.74	-41.15	-49.71	-53.1	-59.76
Interest & Investment Income	17.29	20.96	21.88	18.83	16.79	11.58
Currency Exchange Gain (Loss)	13.23	19.09	15.42	10.53	-4.18	-24.78
Other Non Operating Income (Expenses)	0.06	-3.41	-2.72	-3.38	-2.45	-4.46
EBT Excluding Unusual Items	452.32	507.53	505.59	442.15	360.72	381.35
Gain (Loss) on Sale of Assets	1.89	1.42	8.73	5.54	2.07	2.49
Asset Writedown	-3.73	-5.12	-10.29	-2.61	-1.88	-4.43
Other Unusual Items	43.33	29.82	28.65	26.7	60.32	32.23
Pretax Income	493.82	533.65	532.69	471.77	421.23	411.64
Income Tax Expense	48.7	46.94	26.58	45.66	59.16	64.52
Earnings From Continuing Operations	445.12	486.71	506.11	426.11	362.07	347.11
Minority Interest in Earnings	-16.74	-16.69	-9.59	-15.05	-13.53	-22.25
Net Income	428.38	470.02	496.51	411.06	348.55	324.86
Net Income to Common	428.38	470.02	496.51	411.06	348.55	324.86
Net Income Growth	-12.95%	-5.33%	20.79%	17.94%	7.29%	8.30%
Shares Outstanding (Basic)	686	682	674	661	627	622
Shares Outstanding (Diluted)	688	688	692	671	627	627
Shares Change (YoY)	-0.39%	-0.54%	3.20%	6.93%	-0.02%	0.86%
EPS (Basic)	0.62	0.69	0.74	0.62	0.56	0.52
EPS (Diluted)	0.62	0.68	0.72	0.61	0.56	0.52
EPS Growth	-12.70%	-5.56%	18.03%	9.75%	6.89%	8.33%
Free Cash Flow	332.26	155.19	-59.85	513.48	9.89	140
Free Cash Flow Per Share	0.48	0.23	-0.09	0.77	0.02	0.22
Dividend Per Share	0.250	0.275	0.250	0.200	0.150	0.150
Dividend Growth	-9.09%	10.00%	25.00%	33.33%	-	25.00%
Gross Margin	20.64%	23.45%	28.66%	26.50%	26.46%	29.33%
Operating Margin	5.56%	6.03%	6.32%	6.21%	6.15%	7.64%
Profit Margin	5.12%	5.55%	6.13%	5.48%	5.31%	5.41%
Free Cash Flow Margin	3.97%	1.83%	-0.74%	6.84%	0.15%	2.33%
EBITDA	1,019	1,049	1,026	952.48	840.2	842.97
EBITDA Margin	12.17%	12.40%	12.67%	12.70%	12.81%	14.04%
D&A For EBITDA	554.24	538.84	514.09	486.61	436.53	384.2
EBIT	465.07	510.63	512.15	465.87	403.67	458.77
EBIT Margin	5.56%	6.03%	6.32%	6.21%	6.15%	7.64%
Effective Tax Rate	9.86%	8.80%	4.99%	9.68%	14.04%	15.68%
Revenue as Reported	-	-	-	7,503	-	6,006
Advertising Expenses	-	7.46	8.95	8.18	11.33	12.84

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.